Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-14 00:00:00 ET · period of report 2023-02-10 · accession 0001209191-23-009182 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-14 | 2023-02-13 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $298.92 | -4,887 | 82.0K | -6% | -$1.46M |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $296.84 | -9,362 | 86.9K | -10% | -$2.78M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-13 | S | D | 2,028 | $298.42 | 84,617 | D | — | — | (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $298.42 (range $297.85 to $298.80). |
| 2 | Common | Common Stock | 2023-02-13 | S | D | 1,779 | $299.26 | 82,838 | D | — | — | (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F5) Open market sales reported on this line occurred at a weighted average price of $299.26 (range $298.86 to $299.81). |
| 3 | Common | Common Stock | 2023-02-13 | S | D | 245 | $296.44 | 86,645 | D | — | — | (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $296.44 (range $295.84 to $296.57). |
| 4 | Common | Common Stock | 2023-02-10 | F | D | 3,372 | $294.33 | 92,880 | D | — | — | |
| 5 | Common | Common Stock | 2023-02-13 | S | D | 835 | $300.13 | 82,003 | D | — | — | (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F6) Open market sales reported on this line occurred at a weighted average price of $300.13 (range $299.93 to $300.53). |
| 6 | Common | Common Stock | 2023-02-13 | F | D | 5,990 | $298.26 | 86,890 | D | — | — |